Newsroom | 60181 results

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases, today announced a new analysis of efficacy and biomarker data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC) from the Phase 1/1b ARC-20 study. These data will be presented in a post...

NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced its presence at the American Society of Genitourinary Cancers Symposium happening from February 26-28, 2026, in San Francisco, California. Flatiron's real-world data and research capabilities are featured across multiple presentations, including 6 research acceptances spanning genitourinary cancers. A cornerstone of Flatiron’s presence at ASCO GU 2026 is the global prostate cancer and bladder cancer Panoramic datasets, which draw from o...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate at three upcoming investor conferences: TD Cowen's 46th Annual Health Care Conference Fireside Chat: Monday, March 2, 2026 at 11:10 a.m. Eastern Time in Boston, MA The Citizens Life Sciences Conference Fireside Chat: Wednesday, March 11, 2026 at 1:05 p.m. Eastern Time in Miami Beach, FL Live webcasts will be accessible on the company’s website, acadia.com, under the investors section...

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational progress for the fourth quarter and year ended December 31, 2025. Clinical & Operational Updates Operational progress continues with ivonescimab (SMT112), an investigational, potentially first-in-class bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesi...

BASEL, Zwitserland--(BUSINESS WIRE)--Swiss Rockets AG maakt bekend dat haar CoolMPS 600 mid-throughput sequencer met geavanceerde chemie en nieuwe MPS/NGS-readlengte in het tweede kwartaal van 2026 beschikbaar wordt. Mogelijk gemaakt door haar exclusieve licentie van CoolMPS-technologie, ontwikkelt Swiss Rockets AG sinds augustus 2025 haar eerste sequencer, CoolMPS 600, via contract-R&D met Complete Genomics. Het platform maakt gebruik van de eigen CoolMPS™-chemie van het bedrijf, gebaseerd...

COLUMBUS, Ohio--(BUSINESS WIRE)--The U.S. Environmental Protection Agency recently awarded Battelle one of three blanket purchase agreements to compete for research tasks to evaluate chemicals that may harm the endocrine system in animals and humans. Battelle and two other companies will bid on call orders with a total ceiling value of $44 million over five years to identify potential endocrine-disrupting chemicals and evaluate hazards, exposures, and risks to human health and the environment....

BASILEA, Svizzera--(BUSINESS WIRE)--Swiss Rockets AG annuncia che CoolMPS 600, il suo sequenziatore a media produttività con chimica avanzata e nuova lunghezza di lettura MPS/NGS diventerà disponibile nel secondo trimestre 2026. Grazie alla sua licenza esclusiva di tecnologia CoolMPS, Swiss Rockets AG sta sviluppando il suo primo sequenziatore, CoolMPS 600, attraverso attività di ricerca e sviluppo a contratto con Complete Genomics fin dall'agosto 2025. La piattaforma sta utilizzando la tecnolo...

BÂLE, Suisse--(BUSINESS WIRE)--Swiss Rockets AG annonce que son séquenceur à débit moyen CoolMPS 600, présentant une chimie avancée et une nouvelle longueur de lecture MPS/NGS, sera disponible au deuxième trimestre 2026. Grâce à sa licence exclusive de la technologie CooIMPS, Swiss Rockets AG développe son premier séquenceur, le CoolMPS 600, dans le cadre d'un contrat de R&D avec Complete Genomics depuis août 2025. La plateforme utilise la chimie CoolMPS™, une technologie exclusive à base d...

BASILEA, Suiza--(BUSINESS WIRE)--Swiss Rockets AG anuncia que su secuenciador de rendimiento medio CoolMPS 600 con química avanzada y nueva longitud de lectura de secuenciación masiva paralela (MPS)/secuenciación de nueva generación (NGS) estará disponible en el segundo trimestre de 2026. Gracias a la licencia exclusiva de la tecnología CoolMPS, Swiss Rockets AG está desarrollando su primer secuenciador, CoolMPS 600, a través de una iniciativa de I+D por contrato junto a Complete Genomics desde...